Siponimod for multiple sclerosis-Reference-Cited by-同舟云学术

Siponimod for multiple sclerosis

Published:2021-11-16 Issue:12 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Cao Liujiao¹²,Li Meixuan³,Yao Liang⁴,Yan Peijing⁵,Wang Xiaoqin⁶,Yang Zhen⁷,Lao Yongfeng⁸,Li Huijuan⁹,Yang Kehu¹⁰¹¹,Li Ka¹²

Affiliation:

1. West China School of Nursing/West China Hospital; Sichuan University; Chengdu China

2. School of Public Health, Evidence-Based Social Science Research Center; Lanzhou University; Lanzhou China

3. Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China

4. Department of Health Research Methodology, Evidence and Impact; McMaster University; Hamilton Canada

5. Department of Epidemiology and Health Statistics; West China School of Public Health and West China Fourth Hospital, Sichuan University; Chengdu China

6. The Michael G. DeGroote Institute for Pain Research and Care; McMaster University; Hamilton Canada

7. Department of Rheumatology; Tung Wah Group of Hospitals; Hong Kong China

8. The Second Clinical Medical College; Lanzhou University; Lanzhou China

9. School of Public Health, Evidence-Based Social Science Research Center; Lanzhou University; Lanzhou City China

10. Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China

11. Lanzhou University Institute of Health Data Science; Lanzhou University; Lanzhou China

12. West China School of Nursing /West China Hospital; Sichuan University; Chengdu China

Publisher

Wiley

Subject

Pharmacology (medical)

Reference90 articles.

1. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study;Kappos;Lancet,2018

2. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study;Selmaj;Lancet Neurology,2013

3. Evidence for improved myelination in patients treated with siponimod: Results from the Phase 3 EXPAND MRI Substudy;Arnold;European Journal of Neurology,2020

4. Safety and tolerability of conversion to siponimod in patients with relapsing multiple sclerosis: Interim results of the exchange study;Bar-Or;Multiple Sclerosis Journal,2020

5. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses;Benedict;Neurology,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications;European Journal of Medicinal Chemistry;2024-05

2. Comparison of Prognosis and Cognitive Function of Holistic Neurological Disease: Tochigi Neurological Disease Cohort Study;Journal of Alzheimer's Disease;2024-03-05

3. The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma;Cancers;2024-01-29

4. Assessing neuroprotective effects of diroximel fumarate and siponimod via modulation of pacemaker channels in an experimental model of remyelination;Experimental Neurology;2024-01

5. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis;Drugs in R&D;2023-08-28